Display Settings:

Format

Send to:

Choose Destination
    Arch Phys Med Rehabil. 1997 Mar;78(3):245-50.

    Piracetam as an adjuvant to language therapy for aphasia: a randomized double-blind placebo-controlled pilot study.

    Source

    Department of Neurology, School of Logopedics, Rheinisch-Westfalische Technische Hochschule (RWTH), Braine-l'Alleud, Belgium.

    Abstract

    OBJECTIVE:

    To determine whether piracetam 4.8 g/day together with intensive language therapy improved language function more than language therapy alone.

    DESIGN:

    Double-blind, placebo-controlled parallel group study.

    SETTING:

    Referral speech and language clinic of a university department of neurology.

    PATIENTS:

    Sixty-six inpatients with aphasia present between 4 weeks and 36 months.

    INTERVENTIONS:

    Intensive language therapy for 6 weeks in all patients. Thirty-two patients received piracetam 4.8 g daily and 34 patients received placebo.

    MAIN OUTCOME MEASURE:

    The Aachen Aphasia Test (AAT), a standardized procedure for evaluating the severity of aphasia, was performed at baseline and after 6 weeks' treatment.

    RESULTS:

    In 50 patients evaluated for efficacy, a trend toward improvement in the active group was observed in all subtests of the AAT. This trend was statistically significant for absolute differences in recovery of "written language" and "profile level."

    CONCLUSION:

    Piracetam appears to have a positive adjuvant effect on the recovery of aphasia in patients receiving intensive language therapy.

    PMID:
    9084344
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk